NIVATS Versus IGAVATS: a Pilot Trial Addressing Biopsy Quality in Undetermined Interstitial Lung Diseases

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18+
SponsorUniversity Hospital, Montpellier

About this trial

The main objective of this study is to compare two independent groups of patients requiring lung biopsy for undetermined interstitial lung disease (ILD) in terms of diagnostic confidence as determined by histologists.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Patient with purported interstitial lung disease

Patient requiring a surgical lung biopsy to reinforce diagnosis according to current recommendations and validated by a multidisciplinary assessment

Minimum age: 18 years

Disqualifiers

Contra-indication for surgery

Uncontrolled oesophageal gastric reflux despite optimal treatment

Thoracic deformation (For example, pectus excavatum/carinatum or major scoliosis)

Risk of pleural adhesion (For example, patient who has already undergone thoracic surgery)

Trial design

Design model

Parallel

Treatments tested in this trial

  • Non-intubated video-assisted thoracic surgery (NIVATS) for lung biopsy

    Procedure/Surgery

    An epidural anaesthesia associated with mild sedation requiring no ventilation is used.

  • Intubated general anaesthesia video-assisted thoracic surgery (IGAVATS) for lung biopsy

    Procedure/Surgery

    Uses a traditional deep anaesthesia and one-lung ventilation

Treatment groups

24 Participants
are divided into 2 treatment groups
Group A: NIVATSExperimental treatment 1 intervention
Group B: IGAVATSActive comparator 1 intervention

Trial outcomes

Primary outcomes

1

The level of diagnostic confidence based on centralized histology only

The level of diagnostic confidence for a given diagnosis is established according to a quantitative scale ranging from '0' (absolute rule-out) to '10' (diagnostic certainty). A visual guide for scale use is provided with scores \<1 corresponding to "alternate diagnosis", scores \>=1 and \<4 corresponding to "indeterminate", scores \>=4 and \<7 corresponding to "probable", and scores \>=7 corresponding to "highly probable" categories.

Time frame
Day 1 to day 15

Secondary outcomes

1

The level of diagnostic confidence based on routine histology only

The level of diagnostic confidence for a given diagnosis is established according to a quantitative scale ranging from '0' (absolute rule-out) to '10' (diagnostic certainty). A visual guide for scale use is provided with scores \<1 corresponding to "alternate diagnosis", scores \>=1 and \<4 corresponding to "indeterminate", scores \>=4 and \<7 corresponding to "probable", and scores \>=7 corresponding to "highly probable" categories.

Time frame
Day 1 to day 15
2

The level of diagnostic confidence achieved at multidisciplinary assessment (MDA)-2

The level of diagnostic confidence for a given diagnosis is established according to a quantitative scale ranging from '0' (absolute rule-out) to '10' (diagnostic certainty). A visual guide for scale use is provided with scores \<1 corresponding to "alternate diagnosis", scores \>=1 and \<4 corresponding to "indeterminate", scores \>=4 and \<7 corresponding to "probable", and scores \>=7 corresponding to "highly probable" categories.

Time frame
Day 7 to day 28
3

Change in the level of diagnostic confidence for the most favoured diagnosis between multidisciplinary assessment (MDA)-1 and multidisciplinary assessment (MDA)-2

The level of diagnostic confidence for a given diagnosis is established according to a quantitative scale ranging from '0' (absolute rule-out) to '10' (diagnostic certainty). A visual guide for scale use is provided with scores \<1 corresponding to "alternate diagnosis", scores \>=1 and \<4 corresponding to "indeterminate", scores \>=4 and \<7 corresponding to "probable", and scores \>=7 corresponding to "highly probable" categories.

Time frame
Day 7 to day 28
4

Classification according to ATS/ERS at MDA-1

Classification according to the American Thoracic Society / European Respiratory society: Alternative diagnosis / Indeterminate / Probable / Highly probable

Time frame
Day -28 to day -3

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

University Hospital, Montpellier

Lead sponsor

Grace Asso (Groupe francophone de Réhabilitation Améliorée après Chirurgie)

Collaborator